Navigation Links
Treatment Rates of Prevalent Chronic Conditions Are Low in Brazil, According to Kantar Health Research
Date:9/13/2013

New York, NY (PRWEB) September 13, 2013

Treatment rates for the 10 most prevalent chronic conditions in Brazil generally ranged between 19 percent and 40 percent, according to new findings from Kantar Health’s National Health and Wellness Survey (NHWS). The research will be presented today at the ISPOR (International Society for Pharmacoeconomics and Outcomes Research) 4th Latin America Conference in Buenos Aires.

Among the most prevalent conditions in Brazil, only hypertension had a treatment rate above 50 percent, with 68 percent of patients being treated. However, many chronic conditions, particularly psychiatric ones, had poor treatment rates despite these conditions being significantly debilitating. The most debilitating chronic conditions according to respondents to the NHWS were depression (treatment rate: 39 percent), anxiety (24 percent) and insomnia (19 percent).

“Despite the high prevalence of chronic conditions in Brazil, treatment rates are particularly poor,” said Dave Pomerantz, Senior Vice President, Kantar Health. “The exception was hypertension, which may be related to the free distribution of medicine for hypertension via the Farmacia Popular do Brasil. However, many conditions—especially psychiatric conditions—have low treatment rates despite being associated with worse patient outcomes, meaning that, from a public health perspective, it’s imperative to place more emphasis on the proper management of chronic diseases in Brazil.”

Visit Kantar Health’s website to download the full poster, “Societal Unmet Needs in Brazil: Examining Prevalence, Treatment Rates and Health Outcomes.”

About the National Health and Wellness Survey (NHWS)
The study’s results were drawn from the 2011 and 2012 Brazil NHWS, a nationally representative, self-administered survey conducted annually. Topics covered include the health status, attitudes, behaviors and outcomes among adults 18 or older.

Kantar Health conducts the NHWS in the U.S., Europe, Asia and Latin America. The survey is the largest self-reported dataset in the healthcare industry.

About Kantar Health
Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech, and medical device and diagnostic companies. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership.

Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 700+ healthcare industry specialists work across the product lifecycle, from preclinical development to launch, acting as catalysts to successful decision-making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. For more information, please visit http://www.kantarhealth.com.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11108005.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Exposure/ritual prevention therapy boosts antidepressant treatment of OCD
2. Refractory Hematological Malignances Treatment Opportunities Discussed in MP Advisors Report Published at MarketPublishers.com
3. Study suggests antioxidant treatment may help NF1-linked behavioral issues
4. Low dose antibiotic treatment of C-difficile as effective as high dose in hospital setting
5. Brachytherapy to treat cervical cancer declines in US, treatment associated with higher survival
6. EcoBeauty Brand Lotus Moon Reformulates Skin Regen®, a Leading Organic Scar-Healing Treatment
7. Mount Sinai Grants Exclusive License to Plexcera Therapeutics to Develop Treatments for Farber Disease and Cystic Fibrosis
8. Gulf Coast Spine Care Updates Pinched Nerve Treatment Options
9. Pregnancy Miracle Review Reveals Effective Infertility Treatment
10. Congratulations Congresswoman Maxine Waters for Being Named Co-chair of the Alzheimer’s Task Force;* Now it is Time to Broadly Implement the Treatment that Reverses and Stabilizes this Disease
11. Treatment For Ringing In The Ears
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... ... 'Tis the season for family, festivity, food and fun! Temptation abounds, and parties ... healthy, staying active, and taking medication and doing daily foot health checks (a must ... trips, parties and family gatherings can take their toll on our feet during the ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... authorized OSHA Training Institute Education Center headquartered in Northern California, has announced the ... providing occupational safety and health training to public sector employees. , “The primary ...
(Date:12/5/2016)... ... 2016 , ... Edward Buckingham MD , and the ... the newest Sciton laser in January 2017. The Halo is the first and ... wavelengths for exceptional results. Outperforming more traditional lasers, the innovative Halo automatically customizes ...
(Date:12/5/2016)... Petersburg, Fla. (PRWEB) , ... December 05, 2016 , ... ... concussions have on the growing brains of young athletes. Over the course of three ... the head through unique mouth guards. The mouth guards, equipped with special sensors, will ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... company will provide alerting technology to Central Illinois Health Information Exchange (CIHIE) ... in federal funds as the sole sub-recipient participating with the Illinois Health ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... LAKE OSWEGO, Ore. , Dec. 5, 2016 /PRNewswire/ ... in the BioInsight clinical study. The study evaluates the ... 2 insertion procedure in an office setting. ... ProMRI ® technology that is placed underneath a ... atrial fibrillation and syncope (fainting). Atrial fibrillation is a ...
(Date:12/5/2016)... and Gateway Health proudly announce a dynamic collaboration that will ... members with specific high risk needs. In an ... of consumers, Wellbridge combines technology and population expertise with a ... daily behaviors and lifestyle. ... , , "Dealing ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, ... Sankyo) today announced preliminary safety and efficacy data ... investigational oral selective MDM2 inhibitor, suggesting that DS-3032 ... including relapsed/refractory acute myeloid leukemia (AML) and high-risk ... escalation part of the phase 1 study of DS-3032 ...
Breaking Medicine Technology: